Pulmonary Embolism Management

Indications and Contraindications

• Thrombolytic therapy is strongly indicated for patients with high-risk pulmonary embolism (PE) presenting with hemodynamic instability, defined as systolic blood pressure <90 mmHg or a decrease in systolic blood pressure ≥40 mmHg from baseline, according to the European Heart Journal guidelines 1, 2
• The primary indication for thrombolytic therapy is hemodynamic instability, with a strong recommendation (Class I) by major guidelines, including the European Heart Journal 1, 2
• Thrombolytic therapy may be considered in patients with evidence of right ventricular dysfunction and myocardial injury, as suggested by the European Heart Journal guidelines 2
• In pregnant women with acute PE and life-threatening hemodynamic instability, thrombolytic therapy is suggested in addition to anticoagulation, based on limited evidence from case reports and case series 3
• Absolute contraindications to thrombolysis include active internal bleeding, recent surgery or obstetrical delivery, previous intracranial hemorrhage, intracranial malignancy, and stroke within the past 3 months 1
• Relative contraindications include thrombocytopenia or coagulopathy, severe hepatic or renal disease, pregnancy, and current use of anticoagulants 1, 3

Alternative Approaches

• Surgical pulmonary embolectomy is recommended for patients with high-risk PE when thrombolysis is contraindicated or has failed, as suggested by the European Heart Journal guidelines 2
• Catheter-directed thrombolysis may be considered in patients with high bleeding risk or failed systemic thrombolysis, based on guidelines from the European Heart Journal 2
• Systemic thrombolysis is preferred over catheter-directed thrombolysis for PE, with a standard dose of Alteplase 100 mg IV over 2 hours 1, 4
• Catheter-directed thrombolysis should be considered in patients with high bleeding risk, failed systemic thrombolysis, or shock likely to cause death before systemic thrombolysis can take effect, with a lower dose of thrombolytic 5, 6

Diagnosis of Submassive PE

4

Risks and Benefits

• Thrombolytic therapy is associated with an increased risk of major bleeding (OR 2.84; 95% CI 1.92-4.20) and intracranial hemorrhage (OR 3.17; 95% CI 1.19-8.41), particularly in elderly patients 1
• However, thrombolytic therapy can reduce mortality (OR 0.61; 95% CI 0.40-0.94) and recurrence of PE (OR 0.54; 95% CI 0.32-0.91) in high-risk patients 1, 2
• Mortality in submassive PE with modern anticoagulation is less than 5%, and the benefit of thrombolysis in submassive PE remains controversial, with benefits and risks finely balanced 6, 5

Management and Monitoring

• Full anticoagulation should be continued after thrombolysis, and antiplatelet drugs should be avoided in the first 24 hours after thrombolysis 1
• Close monitoring for bleeding complications, particularly intracranial hemorrhage, is essential, along with monitoring for clinical improvement in hemodynamic parameters 1, 2
• Patients with hemodynamic compromise, defined as systolic BP <90 mmHg or drop ≥40 mmHg from baseline, or signs of shock or hypoperfusion, should receive systemic thrombolysis followed by anticoagulation 1
• Normotensive patients with submassive PE and RV dysfunction should start anticoagulation alone and be monitored closely, with consideration of thrombolysis if signs of clinical deterioration occur, such as decrease in systolic BP, increase in heart rate, or worsening gas exchange 1, 5
• Advanced age alone is not a contraindication to thrombolysis in high-risk PE, and younger patients with low bleeding risk may be considered for thrombolysis in submassive PE 1
• Centers with appropriate infrastructure and experience may consider catheter-directed thrombolysis for patients with intermediate to high bleeding risk 1
• Surgical embolectomy should be considered in patients with contraindications to thrombolysis or failed thrombolysis 6